Amprius Technologies Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
On April 24, 2024, Jonathan Bornstein, our President of Amprius Lab, terminated his stock trading plan that had been intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 Plan”). Mr. Bornstein’s Rule 10b5-1 Plan, adopted on May 12, 2023 with an initial expiration date of December 19, 2024, had provided for the potential exercise of stock options and the associated sale of up to 2,183,851 shares of our common stock.
During the quarter ended June 30, 2024, no other director or officer, as defined in Rule 16a-1(f), adopted orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.